Weeks 1–2
Steadier daytime energy is reported in clinic literature; track subjective notes and sleep timing.
Protocol / Research Dosing Guide
MOTS-c Dosage Guide: Research Schedule, Reconstitution and Safety
An evidence-organized MOTS-c reference separating the strong animal and cell literature from the research-planning schedules that circulate for human use.
Last reviewed September 16, 202618 minute readResearch information only
Level 2 — Animal and cell researchNo human randomized trial of native MOTS-cNot FDA approved; WADA prohibited at all times
MOTS-c Quick Start
MOTS-c is a peptide encoded inside mitochondrial DNA rather than the nuclear genome. Its most studied action is activation of AMPK, the cellular energy switch, which is why it appears in metabolic and exercise-capacity research. The evidence weight sits firmly in animal and cell work; there is no published randomized controlled trial of native MOTS-c in humans.
Why researchers care
AMPK signaling, metabolic flexibility, exercise capacity and aging research
Class
16-amino-acid mitochondria-derived peptide encoded in the 12S rRNA region
Route reported
Subcutaneous injection in animal studies and reported research planning
Cycle length
Reported 4–8 week blocks with 4–8 week off periods
Regulatory status
Not FDA approved; removed from FDA 503A Category 2 in April 2026 without being added to the Bulks List
Loading supplier information
MOTS-c Dosing Protocol and Schedule
The supplied source reports a research-planning anchor of 5 mg subcutaneously, two to three times per week for four to eight weeks, with an upper tier of 10 mg two to three times weekly. It states that none of these tiers has been validated in a published human randomized trial.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Lower tier | 5 mg, twice weekly, 4 weeks | Community and clinic planning |
| Standard tier | 5 mg, three times weekly, 4–6 weeks | Community and clinic planning |
| Higher tier | 10 mg, two to three times weekly, 6–8 weeks | Community and clinic planning |
| Conservative cycle | 4 weeks on, 4 weeks off | Community and clinic planning |
| Standard cycle | 6 weeks on, 4–6 weeks off | Community and clinic planning |
| Extended cycle | 8 weeks on, 6–8 weeks off | Community and clinic planning |
Smaller, more frequent amounts are described as a way to keep AMPK signaling steadier given the short estimated half-life. Larger weekly totals did not add benefit in the published animal work and are reported to raise side effects. No published human trial has compared cycle lengths.
MOTS-c Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Bacteriostatic water at a measured volume
Research planning item
1 mL / 100-unit U-100 insulin syringes, since a 5 mg draw at 10 mg/mL is 0.5 mL
Research planning item
Alcohol prep swabs
Research planning item
Sharps container
Research planning item
Refrigeration for the prepared vial
Research planning item
Written concentration label with the preparation date
MOTS-c Reconstitution Calculator
Vial-format concentration math
Concentration
10 mg/mL
Draw volume
0.5 mL
U-100 units
50
Mathematical draws
2
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take MOTS-c: Morning or Night?
Morning or evening?
Not established. No study compared times of day.
Daily or spaced?
Reported planning is two to three times per week, not daily. Daily 1 mg patterns appear in one community source and are not the dominant pattern.
With food?
Not applicable to an injected product.
Missed amount?
Reported protocol convention is to skip to the next scheduled administration rather than double up.
MOTS-c Route Comparison
| Format | What is reported | Evidence limit |
|---|---|---|
| Subcutaneous | The route used in animal studies and reported research planning | Not validated in a human trial |
| Intraperitoneal | Used in several rodent studies | Animal route; not applicable to human planning |
| Oral | Not a viable route for this peptide | No exposure data |
| Route conversion | Not established | Animal administration does not convert into a human amount |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
MOTS-c Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human half-life | Not established in a published human study | Do not infer frequency |
| Estimated short half-life | Cited as the reason smaller, more frequent amounts are preferred in planning | An estimate, not a measured figure |
| Frequency logic | Two to three times weekly is a planning convention | Not validated |
| Repeat-cycle interval | Not established | Cycle structures are community conventions |
MOTS-c Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 5 mg | Twice weekly | Community/clinic planning | No |
| Subcutaneous | 5 mg | Three times weekly | Community/clinic planning | No |
| Subcutaneous | 10 mg | Two to three times weekly | Community/clinic planning | No |
| Animal studies | Varies by model | Varies by protocol | Animal research | Not convertible |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
MOTS-c Reconstitution Guide
Concentration: 10 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 5 mg | 0.5 mL | 50 units |
| 10 mg | 1 mL | 100 units |
- 1.Confirm the vial quantity, commonly 10 mg.
- 2.Add 1.0 mL of bacteriostatic water for 10 mg/mL.
- 3.Clean the stopper with an alcohol swab.
- 4.Add the liquid slowly down the vial wall.
- 5.Swirl gently until clear; do not shake.
- 6.At 10 mg/mL a 5 mg draw is 0.5 mL, which is 50 units on a U-100 syringe, and one vial covers two such draws.
- 7.Label the vial with the concentration and preparation date.
- 8.Refrigerate and use within the supplier-stated window; MOTS-c is reported as heat and time sensitive.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How MOTS-c Works
Mitochondrial origin
MOTS-c is encoded within mitochondrial DNA rather than the nuclear genome, making it a mitochondria-derived signaling peptide.
MOTS-c Human Trials and FDA Status
Current status · verified September 16, 2026
Not FDA approved; removed from FDA 503A Category 2 in April 2026 without being added to the Bulks List
- Lee et al. 2015 (Cell Metabolism) reported reduced obesity and insulin resistance in high-fat-diet mice.
- Reynolds et al. 2021 (Nature Communications) reported improved running capacity across mouse age groups.
- Kumagai et al. 2021 reported reduced myostatin and atrophy signaling in mice.
- Domin et al. 2023 reported a correlation between higher serum MOTS-c and lower-body strength in healthy adults; this is cross-sectional, not an intervention trial.
- CB4211, a synthetic MOTS-c analogue, completed a Phase 1a/1b trial reported as safe and well tolerated. It is a related but different molecule.
- No published human randomized controlled trial has tested native MOTS-c for any clinical endpoint.
Who Should Avoid MOTS-c?
This is an evidence-gap and precaution list, not an approved prescribing label.
Active cancer
Direction of effect is not settled; an active diagnosis is a stated hold reason
Pregnancy or breastfeeding
No safety data
People taking metformin, aspirin or thiazolidinediones
Overlapping AMPK activation with unknown net effect
Tested athletes
MOTS-c is named on the 2026 WADA Prohibited List under AMPK activators and is banned at all times
Children or adolescents
No established protocol
Anyone relying on product purity claims
Research-grade material can carry impurities and immunogenicity risk
MOTS-c Side Effects, Risks and Safety
Flushing or itchingReported
Important limitation: Attributed to histamine release; persistent flushing is a stop signal.
Injection-site reactionReported
Important limitation: A small red mark for a few hours is common; swelling or hardness beyond 48 hours is a stop signal.
ImmunogenicityStated risk
Important limitation: Flagged in FDA materials on protein-based therapeutics.
Impurity-related riskProduct dependent
Important limitation: Research-grade quality varies.
Drug interactionsUnknown
Important limitation: AMPK overlap with metabolic medicines is the stated concern.
Long-term safetyUnknown
Important limitation: No human trial of native MOTS-c.
MOTS-c Timeline and Monitoring
Weeks 3–4
Workout tolerance and recovery are described as smoother; track workout logs.
Weeks 4–6
Body-composition shifts described in animal protocols may appear, without randomized confirmation; track waist circumference and fasting glucose if available.
End of cycle
A review point. Compare baseline to end-of-cycle notes rather than extending without review.
MOTS-c Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Metabolic flexibility | Animal research | High-fat-diet mouse studies | No human trial |
| Exercise capacity | Animal research | Running-capacity improvement in mice | No human trial |
| Muscle preservation | Animal research | Reduced myostatin and atrophy signaling in mice | No human trial |
| Strength in humans | Correlational only | Serum MOTS-c correlated with lower-body strength | Association, not causation |
MOTS-c Storage and Handling
Lyophilized powder
About -20 °C for long-term storage; refrigeration at 2–8 °C is acceptable short-term per supplier labeling.
Prepared vial
Refrigerated at 2–8 °C with a reported 2–3 week window.
Heat sensitivity
Reported as more sensitive to heat and time than many research peptides.
Appearance
Discard if cloudy or containing visible particles.
MOTS-c Troubleshooting
Wrong water volume added
2.0 mL instead of 1.0 mL in a 10 mg vial gives 5 mg/mL, so a 5 mg draw becomes 1.0 mL or 100 units. Recalculate before drawing.
Cloudy or speckled vial
Do not use it. Discard.
Strong flushing or itching
Stop and seek qualified medical input before any change.
Injection-site reaction lasting beyond 48 hours
Treat persistent swelling, hardness or warmth as a stop signal.
A prepared vial sat warm for hours
Treat it as compromised.
Confusion about frequency
The reported pattern is two to three times weekly, not daily.
MOTS-c Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| MOTS-c | Mitochondria-derived AMPK activator | Animal and cell research | Not approved; WADA banned |
| Tesamorelin | GHRH analogue raising growth-hormone release | Approved for HIV-associated visceral fat | Approved in one indication |
| SS-31 | Targets cardiolipin in the inner mitochondrial membrane | Mitochondrial repair research | Not approved |
| Metformin | AMPK activator among other effects | Extensive human trials | Approved prescription medicine |
MOTS-c Frequently Asked Questions
What is MOTS-c?
A 16-amino-acid peptide encoded in mitochondrial DNA that acts as a cellular energy signal.
Is it FDA approved?
No. It was removed from FDA 503A Category 2 effective April 22, 2026, which is not the same as being added to the Bulks List.
Is there a human trial?
No randomized controlled trial of native MOTS-c has been published. A synthetic analogue, CB4211, completed Phase 1.
What schedule is reported?
5 mg subcutaneously, two to three times weekly, for four to eight weeks.
How is a 10 mg vial prepared?
Commonly with 1.0 mL of bacteriostatic water for 10 mg/mL, making a 5 mg draw 0.5 mL or 50 units.
What is its half-life?
Not established in a published human study; it is described as short.
Why is it cycled?
Cycling is reported as a way to limit AMPK downregulation and create a review window. No trial has compared cycle lengths.
Is it allowed in tested sport?
No. It is named on the 2026 WADA Prohibited List and is banned at all times.
What are the most reported side effects?
Flushing or itching from histamine release, and injection-site reactions.
What does the calculator do?
Concentration and volume arithmetic only.
Sources and Research
Coverage source
1. MOTS-c protocol coverage source
Research-planning tiers, cycle structures, reconstitution math and regulatory timeline; not primary evidence.
Open direct sourceAnimal research
2. Lee et al., The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis
Cell Metabolism 2015 mouse study on obesity and insulin resistance.
Open direct sourceAnimal research
3. Reynolds et al., MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline
Nature Communications 2021 mouse running-capacity study.
Open direct sourceHuman research
4. Domin et al., Serum MOTS-c and physical performance in healthy adults
Cross-sectional human correlation, not an intervention trial.
Open direct sourceRegulatory
5. WADA 2026 Prohibited List
MOTS-c is named under AMPK activators and prohibited at all times.
Open direct sourceMissing information flagged for review
- Human randomized controlled trial of native MOTS-c: Not established
- Human pharmacokinetics and half-life: Not established
- Validated dose and frequency: Not established
- Validated cycle and rest period: Not established
- Long-term safety: Not established
- Drug interaction data: Not established